AKAndrii V. Kolesnyk

Andrii V. Kolesnyk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrii V. Kolesnyk has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    THE ROLE OF FLOT TOTAL NEOADJUVANT CHEMOTHERAPY REGIMEN IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE STOMACH AND GASTROESOPHAGEAL JUNCTION. A NARRATIVE REVIEW

    by Mykyta O. Pepenin, Arthur M. Khudyntsev, Yurii M. Kondratskyi, Oleksii Yu. Dobrzhanskyi, Andrii V. Kolesnyk, Andrii V. Horodetskyi, Kostiantyn V. Kopchak, Serhii V. Zemskov

    Introduction. Gastric cancer is a leading cause of cancer mortality worldwide, and outcomes for patients with locally advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma remain poor. Perioperative chemotherapy became the standard of care after the MAGIC and FNCLCC/FFCD trials demonstrated improved survival compared with surgery alone. The FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel) subsequently demonstrated superior efficacy and has become the current standard of care. However, many patients do not complete the planned adjuvant chemotherapy because of postoperative complications or disease progression, prompting interest in delivering the entire chemotherapy course preoperatively as total neoadjuvant therapy (TNT) using the FLOT regimen.Aim. To evaluate the efficacy and safety of total neoadjuvant chemotherapy using the FLOT regimen in patients with locally advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma.Materials and methods. A narrative literature review was performed. Relevant studies were identified through searches of Scopus, Web of Science, MEDLINE, Cochrane Library, EMBASE, and Global Health. Key clinical trials (MAGIC, FNCLCC/FFCD, FLOT4, NeoFLOT, ESOPEC, etc.) and retrospective analyses of perioperative and neoadjuvant therapy were analyzed.Results. The MAGIC (UK) and FNCLCC/FFCD (France) trials confirmed that adding chemotherapy to surgery improves patient survival. The FLOT4 trial demonstrated that the FLOT regimen provides superior outcomes compared with ECF, including improved survival and a threefold increase in the pathological complete response (pCR) rate. Moreover, the phase II NeoFLOT trial and an analysis from Memorial Sloan Kettering Cancer Center (MSKCC, 2023) demonstrated the feasibility of total neoadjuvant chemotherapy: NeoFLOT achieved an R0 resection rate of 86% and a pCR rate of 20%, while the MSKCC experience showed that most patients completed all preoperative FLOT cycles without an increase in postoperative complications. In addition, the ESOPEC trial (2024) demonstrated that perioperative FLOT chemotherapy resulted in superior survival outcomes compared with standard neoadjuvant chemoradiotherapy (CROSS) in patients with esophageal and GEJ adenocarcinoma.Conclusions. The introduction of the FLOT regimen has significantly improved the treatment outcomes of locally advanced gastric and GEJ adenocarcinoma by increasing R0 resection rates as well as overall and disease-free survival. Delivering the entire FLOT regimen preoperatively is a promising strategy to ensure completion of systemic therapy and increase pCR rates without compromising surgical outcomes. However, there is currently no definitive evidence that total neoadjuvant FLOT improves long-term survival compared with standard perioperative chemotherapy. Further prospective studies are required, while perioperative chemotherapy remains the current standard of care.

  • Open Access

    Complications of surgical treatment for esophageal leiomyoma: a case series

    by Ye. Kozak, Yu. Kondratskyi, I. Nastashenko, O. Dobrzhanskyi, M. Pepenin, A. Kolesnyk, Ye. Shudrak, A. Horodetskyi, V. Turchak, N. Koval, et al.

    Esophageal leiomyomas are the most common benign tumors of the esophagus. While surgical resection is the definitive treatment for symptomatic cases, it carries a risk of postoperative complications. This study presents a case series on the surgical management of esophageal leiomyomas, with a particular emphasis on postoperative complications and their management. This retrospective case series, conducted at the National Cancer Institute (Kyiv, Ukraine), analyzed patients who underwent surgical treatment for symptomatic esophageal leiomyoma between 2021 and 2024 and developed postoperative complications classified as Clavien-Dindo grade III or higher. Data were collected from medical records, including demographics, tumor charac­teristics, surgical details, postoperative course, complications, management strategies, and outcomes. The total number of observations was n=3. Three cases with Clavien-Dindo III-IV postoperative complications were analyzed. Comp­lications included anastomotic leakage following Ivor Lewis esophagectomy (managed with endoscopic stenting and endoscopic vacuum therapy – EVT), esophageal perforation during enucleation leading to mediastinitis (managed with stenting and endoscopic vacuum therapy), and a complex case involving hemopericardium, post-cardiac arrest syndrome, peritonitis and diaphragmatic herniation requiring multiple reinterventions. Despite the severity of these complications, multidisciplinary management led to complete recovery of all patients. Histopathological evaluation confirmed benign leiomyoma in all cases. Surgical management of esophageal leiomyomas, particularly for large tumors, is often associated with significant postoperative complications. While minimally invasive techniques may reduce these risks, they do not eliminate them entirely. Endoscopic therapy plays a critical role in the non-surgical management of anastomotic leakage and esophageal perforation. Vigilant postoperative monitoring and a multidisciplinary approach are essential for achieving favorable outcomes in these complex cases.

  • Open Access

    Treatment outcomes and quality of life of patients after esophagectomy with simultaneous reconstruction using different gastric grafts

    by E. A. Shudrak, A. V. Horodetskyi, Y. A. Dibrova, A. A. Shudrak, Y. M. Kondratskyi, N. O. Koval, O. Y. Dobrzhanskyi, A. V. Kolesnyk, M. O. Pepenin, E. O. Kozak, et al.

    Objective. To compare short–term postoperative outcomes and quality of life in patients after esophagectomy with simultaneous reconstruction using different gastric grafts. Materials and methods. A prospective single–center cohort study included 195 patients with resectable esophageal or esophagogastric junction cancer who underwent Lewis esophagectomy with restoration of digestive tract continuity using different gastric grafts. The primary endpoints were the incidence of anastomotic failure, intrathoracic complications, mortality, length of hospital stay, and quality of life according to the European Organization for Research and Treatment of Cancer QLQ–OES18 scale. Results. The best results were obtained with a typical gastric graft: fewer complications (31.6%), shorter hospital stay (15.3 ± 4.5 days), and better quality of life, especially in terms of dietary restrictions (p=0.01). Although statistical significance was not achieved for all indicators, a stable trend in favor of this reconstruction option was observed. Conclusions. The option of simultaneous reconstruction after esophagectomy using a typical gastric graft is optimal: the clinical course of the disease and functional results are better than with other options.

  • Open Access

    RISK FACTORS FOR 30-DAY READMISSION AFTER SURGICAL TREATMENT OF GASTRIC CANCER: A SINGLE-CENTER EXPERIENCE

    by Yu. M. Kondratskyi, Н. О. Коваль, A. V. Kolesnyk, Ye. A. Shudrak, O. Yu. Dobrzhanskyi, M. O. Pepenin, A. V. Horodetskyi, Ya. O. Svichkar, I. O. Ukrainets, Ye. O. Kozak, et al.

    The aim of the work: to determine the frequency and risk factors for 30-day readmission after gastrectomy for gastric cancer at a single specialized oncologic center. Materials and Methods. A retrospective single-center cohort study included 145 patients who underwent surgery in 2024. Clinical, demographic, nutritional parameters, comorbidities, type of surgery, and postoperative complications were analyzed. Univariate and multivariate logistic regression was applied to identify independent risk factors. Results. The 30-day readmission rate was 9.7%. The leading causes included gastrointestinal complications, infections, and exacerbation of chronic conditions. Independent risk factors were: sarcopenia (OR=3.92; 95 % CI: 1.54–9.94), postoperative complications Clavien-Dindo ≥II (OR=2.61; 95 % CI: 1.18–5.78), operation time >4 hours (OR=2.45; 95 % CI: 1.01–5.94). The findings are consistent with literature data highlighting the multifactorial nature of readmissions. Nutritional status and frailty play a significant role. Conclusions. Timely assessment of nutritional status, sarcopenia, and enhanced postoperative monitoring can reduce the risk of readmission.

  • Open Access

    Evaluation of different methods of endoscopic papillectomy for adenomas of the major duodenal papilla

    by I. L. Nastashenko, Y. M. Kondratskyi, K. V. Kopchak, Y. O. Svichkar, I. O. Ukrainets, A. V. Kolesnyk, Y. A. Shudrak, O. Y. Dobrzhanskyi, M. O. Pepenin, A. V. Horodetskyi

    Objective – to assess the outcomes of endoscopic papillectomy (EP) using standard techniques, as well as to develop and implement novel surgical intervention approaches. Materials and methods. Between 2021 and 2024, the Department of Interventional Endoscopy at the National Cancer Institute performed EP for adenoma of the major duodenal papilla (MDP) on 19 patients, 10 women (52.63%) and 9 men (47.37%), aged 24 to 78 years, with a mean age of 45.6 years. We observed clinical signs of biliary obstruction and cholangitis in the majority of cases (2 (63.15%)). Results. 10 patients (52.63%) with tumours <1.0 cm underwent the standard procedure of en‑bloc loop resection (Group 1). To prevent intraoperative and postoperative complications, we developed and implemented a two‑stage EP procedure in 6 (31.57%) cases (Group 2). In 3 (15.78%) patients with tumours ranging from 5.0 to 8.0 cm, the piecemeal approach was used to remove all fragments from the area of the neoplasm that reached into the intestinal lumen (Group 3). After a three‑month follow‑up, 2 patients (10.5%) from Group 3 had a recurrence of an adenoma of the MDP. Both cases required loop diathermy excision for recurrent neoplasms and stent removal. Routine tests at 3 and 6 months revealed no evidence of disease progression. Conclusions. The topographic and anatomical characteristics of the MDP area determine the complexity of surgical interventions for patients with neoplasms. The novel EP approach minimizes the risks associated with both early and late postoperative complications. The outcomes achieved by employing EP in the treatment of patients with MDP adenomas support its recommendation as the primary approach at specialized centers.

  • Open Access

    A rare case of complicated hernioplasty and reconstruction of the gastroesophageal junction: multistage treatment with a positive outcome

    by Y. Kondratskyi, N. Koval, A. Kolesnyk, Y. Shudrak, O. Dobrzanskyi, M. Pepenin, V. Turchak, A. Horodetskyi, Y. Svichkar, I. Ukrainets, et al.

    This clinical case presents the complex and multistage management of a 48‑year‑old woman with a recurrent hiatal hernia following previous laparoscopic surgical treatment. The initial surgery was complicated by technical errors, leading to early recurrence of the hernia. Subsequent laparoscopic reintervention included mesh‑reinforced hernioplasty and revision fundoplication. However, the postoperative course was complicated by the development of acute gastric fundus ischemia and necrosis, which necessitated urgent atypical wedge resection of the stomach. Despite initial recovery, the patient later developed further complications, including a mesh‑related gastric ulceration and the formation of a chronic inflammatory infiltrate in the upper abdominal cavity. These adverse events required a relaparotomy, complete mesh removal, proximal gastrectomy, and complex gastrointestinal reconstruction using the double‑tract method. The management of this case illustrates several critical challenges: the risk of ischemic complications following fundoplication, the long‑term sequelae of mesh implantation at the gastroesophageal junction, and the technical considerations necessary for successful reconstruction after proximal gastrectomy. Special attention was paid to minimizing postoperative reflux, preserving nutritional function, and ensuring a high quality of life. This clinical case highlights the importance of careful patient selection, meticulous surgical technique, and the necessity for early recognition and management of postoperative complications. Through a stepwise, multidisciplinary surgical approach, a positive long‑term outcome was achieved, with the patient demonstrating good tolerance to a regular diet, no signs of reflux, and satisfactory functional recovery.

  • Open Access

    Surgical management of oligometastatic recurrence in primary esophageal melanoma: a feasible approach in resource-limited settings

    by Yurii Kondratskyi, Mykyta Pepenin, Andrii Horodetskyi, Oleksii Dobrzhanskyi, Andrii Kolesnyk, Yevhenii Shudrak, Mykhailo Krotevych

    Primary esophageal melanoma (PEM) is a rare and aggressive malignancy with limited treatment options. Due to its rarity, no standardized guidelines exist for managing oligometastatic recurrence, particularly in resource-limited settings. We present a case of a 60-year-old male with PEM who underwent esophagectomy followed by surgical resection of an adrenal metastasis. Despite the increasing use of immunotherapy, surgical resection remains a viable alternative for oligometastatic recurrence when access to systemic therapies is restricted. This case highlights the feasibility of surgery in achieving long-term disease control in select patients. Further studies are needed to establish evidence-based strategies for treating PEM recurrence in resource-constrained environments.

  • Open Access

    THE IMPACT OF SARCOPENIA ON POSTOPERATIVE OUTCOMES IN ESOPHAGEAL CANCER PATIENTS UNDERGOING ESOPHAGECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS

    by Yurii M. Kondratskyi, Yevhenii A. Shudrak, Andrii V. Horodetskyi, Oleksii Y. Dobrzhanskyi, Mykyta O. Pepenin, Yurij A. Dibrova, Andrii V. Kolesnyk

    Introduction. Esophageal cancer remains a major global health challenge, ranking among the leading causes of cancer-related mortality. Esophagectomy, a standard treatment for resectable cases, is associated with high rates of postoperative complications, significantly impacting patient outcomes. Among various risk factors, sarcopenia—a condition characterized by decreased skeletal muscle mass and strength—has emerged as a potential predictor of adverse postoperative outcomes. However, its precise influence on esophagectomy-related morbidity and mortality remains unclear, warranting further investigation. Aim. This systematic review and meta-analysis aimed to evaluate the impact of sarcopenia on early postoperative outcomes in patients undergoing esophagectomy for esophageal cancer. Specifically, we assessed the association between sarcopenia and postoperative complications, anastomotic leakage, and mortality. Materials and methods. A systematic literature search was conducted in MedLine and Cochrane Library Central for studies published between January 2020 and September 2024, adhering to PRISMA guidelines. Eligible studies included cohort studies and clinical trials comparing sarcopenic and non-sarcopenic patients undergoing esophagectomy. Data extraction focused on patient demographics, sarcopenia assessment methods, and postoperative outcomes. A meta-analysis was performed using a random-effects model, with results expressed as log odds ratios and 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic, and publication bias was evaluated through funnel plot asymmetry tests. Results. A total of 10 studies, encompassing 1,382 patients, met the inclusion criteria. The pooled analysis revealed that sarcopenia was significantly associated with an increased risk of postoperative complications (log odds ratio: 0.725, 95% CI: 0.221 to 1.229; p = 0.005), with moderate heterogeneity (I² = 49.3%). However, no significant association was found between sarcopenia and anastomotic leakage (log odds ratio: -0.376, 95% CI: -1.537 to 0.785; p = 0.525), despite high heterogeneity (I² = 74.1%). Similarly, no significant relationship was observed between sarcopenia and postoperative mortality (log odds ratio: 0.803, 95% CI: -2.200 to 3.806; p = 0.600), with moderate heterogeneity (I² = 63.1%). Conclusions. Sarcopenia significantly increases the risk of postoperative complications in esophageal cancer patients undergoing esophagectomy, underscoring the need for preoperative muscle mass assessment and targeted nutritional or rehabilitation interventions. However, its association with anastomotic leakage and mortality remains inconclusive. Further research with standardized sarcopenia definitions and larger patient cohorts is necessary to refine clinical risk stratification and optimize perioperative care strategies.

  • Open Access

    Endoscopic stent placement in the management of esophagojejunal anastomosis leakage

    by O. Dobrzhanskyi, Y. Kondratskyi, E. Kozak, A. Kolesnyk, M. Pepenin, Y. Shudrak, A. Horodetskyi, V. Turchak, A. Omelchak, N. Koval, et al.

    Objective — to evaluate the effectiveness of endoscopic stent placement compared to surgical methods for the management of esophagojejunal anastomosis leakage (AL) after gastrectomy at the National Cancer Institute (NCI) from November 2017 to November 2019. Materials and methods. The study included patients receiving treatment at the Upper Gastrointestinal Oncology Department of the National Cancer Institute between November 2017 and November 2019. Throughout this period, 186 total gastrectomies were performed. 13 (6.9%) patients developed an anastomotic leak in the postoperative period. All patients had Roux‑en‑Y esophagojejunostomy. 6 patients (46.1%) underwent endoscopic stent placement in the AL area, along with perianastomotic drainage positioning and enteral feeding via a naso‑intestinal tube. Of the remaining patients, 7 (53.9%) underwent surgical treatment, including esophagostomy or esophageal stump formation with a nutritional jejunostomy. This manuscript employed methods of descriptive statistics. Results. Endoscopic stent placement was successful for 5 patients. Complete defect closure following stent placement was confirmed in 5 patients (83.3%) using endoscopic and radiological methods. The mean hospital stay in the stent group was 15.4 days (range: 9—22 days). The mean time for endoscopic stent removal during rehospitalization was 49.5 (33—62 days) days after initial placement. Complications associated with AL, specifically sepsis resulting from infection in the AL area, led to the death of 1 (16.7%) patient in the stent group. Surgical treatment was successful in 5 patients (71.4%). 2 patients (28.6%) died due to infectious complications and multiple organ failure syndrome. The average hospital stay for surgical patients was 32.8 (19—40) days. Mortality rates were 16.7% and 28.6% for the stent placement and surgical groups, respectively. Conclusions. Endoscopic endoluminal stent placement in the area of AL using self‑expandable metallic stents combined with local drainage and enteral nutrition is a promising method for treating esophagojejunal anastomotic leakage after total gastrectomy. This study demonstrates that endoscopic stent placement reduces hospital stay and mortality rates compared to surgical methods. Endoscopic stent placement provides effective defect closure with fewer complications. However, surgical treatment remains indispensable in cases of severe sepsis or failure of conservative methods, despite the high mortality risk. Further studies are needed to develop standardized approaches for selecting treatment methods based on leak size and the patient’s overall condition.